NCT00162318View on ClinicalTrials.gov

A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

April 30, 2006

Study Completion Date

April 30, 2006

Conditions
Non-Small-Cell Lung Carcinoma
Interventions
DRUG

Cetuximab + Gefitinib

IV solution + tablet, IV + oral, ERB (100 mg/m2, 200 mg/m2 + 250 mg/m2 IV) +GEF 250 mg tablet, ERB weekly/ GEF once daily, Until disease progression.

Trial Locations (1)

Unknown

Local Institution, Pittsburgh

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT00162318 - A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter